Posted by Michael Wonder on 27 Jun 2017
Sandoz receives approval in Europe for Erelzi (biosimilar etanercept) to treat multiple inflammatory diseases
27 June 2017 - European Commission approves Sandoz Erelzi to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis.
Sandoz announced today that the European Commission has approved Erelzi (biosimilar etanercept) for use in Europe. Erelzi is approved for use in all indications of the reference medicine, Enbrel.
The EC approval was based on a comprehensive development program generating analytical, preclinical, and clinical - including pharmacokinetic - data. The program demonstrated that Erelzi matches its reference medicine in terms of safety, efficacy, and quality.
